An ongoing dialogue on HIV/AIDS, infectious diseases,
June 20th, 2012
Abacavir Becomes the Latest Generic Antiretroviral Agent
Hot on the heels of generic nevirapine comes generic abacavir:
On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Ziagen Tablets, a product of VIIV Healthcare Company.
Note that this is for the separate 300 mg tablets, which are approved for twice-daily dosing, and not (yet) for the convenient coformulated once-daily abacavir/3TC tablet.
Nonetheless, it’s notable that a highly effective, well tolerated regimen — abacavir, 3TC, and efavirenz — could now be two-thirds generic, with the last third (efavirenz) probably becoming generic sometime soon.
Does that mean you’ll be switching your patients to generic abacavir once it appears in pharmacies? Let’s do a poll.
Categories: Health Care, HIV, Patient Care, Policy
Tags: 3tc, Abacavir, antiretroviral therapy, generic drugs
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “Abacavir Becomes the Latest Generic Antiretroviral Agent”

Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
-
-
From the Blog — Most Recent Articles
- DOTS: Optimism Around a “Negative” Dalbavancin Trial October 10, 2025
- Update on Louie and One Interesting ID Fact October 3, 2025
- My Dog Louie, the Best Dog Ever, Is Seriously Ill September 26, 2025
- Two Drugs, Not Three: The DOLCE Study in Advanced HIV Disease September 19, 2025
- When Required Learning Modules Surprise You (In a Good Way) September 10, 2025
NEJM Journal Watch — Recent Infectious Disease Articles
- It's Not Always “Just the Flu”
- RSVpreF Vaccine's Effects on Severe Outcomes of RSV Infection
- Should Early Empirical Mold-Active Antifungals Be Given for Severe Influenza Pneumonia?
- Influenza Immunization for Inpatients with Advanced Heart Failure: Is it Beneficial?
- Another Option for RSV Prevention in Babies is Approved
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
how is abacavir’s mechanism of action?